Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    Escitalopram Decreases Symptoms of Major Depressive Disorder in Adolescents: Presented at AACAP - (DGDispatch)
    TopAbstracts in Depression 11/04/2009 - (DGNews)
    TopAbstracts in Depression 10/29/2009 - (DGNews)
    Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial - (JAMA)
    TopAbstracts in Depression 10/21/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Depression
    Antidepressant-Induced Suicidality: Implications for Clinical Practice
    Treatment-Resistant Depression -- Part III: Switching Antidepressants vs. Conventional Augmentation Strategies

    Webcasts/CME archive

     Recent cases - Depression
      Creutzfeldt-Jacob Disease Presenting as Severe Depression: A Case Report
      Sexual Dysfunction in a Young Mother
      Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
      A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
      Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report

      Cases archive
        




      my personal edition > depression > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Boosting Fluoxetine As Effective As Adding Lithium Or Desipramine For Unresponsive Depression

      A DGReview of :"Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine"
      Journal of Clinical Psychopharmacology

      08/30/2002
      By Andrew A. Skolnick


      Boosting the dosage of fluoxetine is as effective as adding either lithium or desipramine in treating depression that doesn't respond adequately to fluoxetine.

      Maurizio Fava, MD, at the Massachusetts General Hospital in Boston, United States, and colleagues conducted a double blind clinical trial involving 101 outpatients with major depressive disorder, who either didn't respond or failed to respond adequately to eight weeks of treatment with fluoxetine 20 mg a day.

      The 52 men and 49 women were randomized to received either four weeks of treatment with high-dose fluoxetine (40-60 mg/day), fluoxetine plus lithium (300-600 mg/day), or fluoxetine plus desipramine (25-50 mg/day).

      The researchers found no significant difference in response rates across the three treatment groups. Forty-two percent of patients responded on high-dose fluoxetine, 29 percent responded on fluoxetine plus desipramine, and 23 percent responded on fluoxetine plus lithium, they reported.

      There were also no significant differences in response rates for the three treatment groups among either the 49 partial responders or 52 nonresponders.

      There were no significant relationships between lithium or desipramine blood levels and degree of improvement, as measured by the change in HAM-D-17 score, the investigators noted.

      Dropout rates also were comparable, ranging from 9.1 percent for patients receiving high-dose fluoxetine to 14.7 percent for patients in the other two treatment groups.

      "We found no significant differences in efficacy among these three treatment strategies among patients who had failed to respond adequately to eight weeks of treatment with fluoxetine 20 mg/day, although the high-fluoxetine group was associated with nonsignificantly higher response rates in both partial responders and nonresponders," the researchers concluded.
      J Clin Psychopharmacol 2002; 22: 379-387 "Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send